463 research outputs found

    Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits

    Get PDF
    Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies. A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy for cervical cancer at Washington University between July 1, 2005 and December 31, 2015. Wilcoxon rank-sum exact test and Fisher's exact test were used to compare the treatment groups, and Kaplan Meier curves were generated. Cox regression analyses were performed, with treatment free interval and prior therapy response included as covariates. Of 84 patients who received PB chemotherapy, 59 (70%) received no second line chemotherapy, as they did not recur, progressed without further chemotherapy, were lost to follow up, or expired. Of the remaining 25 patients, 9 were retreated with the combination of platinum/bevacizumab (PB), 6 were retreated with a platinum regimen without bevacizumab (P), and 10 were retreated with neither (not-P). The only long-term survivor was in the not-P group and was treated with an immunotherapy agent. Median overall survival of all patients was 7.1 months. There was a marginal difference in survival between women in the PB and not-PB groups (11.8 versus 5.7 months; HR 3.02, 95% CI, 0.98–9.28). There was no difference in survival based on platinum interval (HR 0.81; 95% CI, 0.27–2.45). Outcomes are grim for women retreated after platinum/bevacizumab therapy and are only marginally improved by retreatment with a platinum/bevacizumab regimen. Rather than additional PB therapy, women with cervical cancer who recur after platinum/bevacizumab should consider supportive care or clinical trials

    SoroprevalĂȘncia do parvovĂ­rus humano B19 em população de subĂșrbio no Estado de SĂŁo Paulo, Brasil

    Get PDF
    OBJETIVO: Analisar a prevalĂȘncia de anticorpos IgG ao parvovĂ­rus humano B19. MÉTODOS: Estudo transversal em uma comunidade de subĂșrbio de SĂŁo Paulo, Brasil, de novembro 1990 a janeiro de 1991. Amostras aleatĂłrias (N=435) e representativas de soro foram coletadas de crianças sadias a partir de 15 dias de idade e de adultos com atĂ© 40 anos. Os anticorpos IgG ao parvovĂ­rus humano B19 foram detectados pelo teste ELISA. RESULTADOS: A prevalĂȘncia de anticorpos IgG ao parvovĂ­rus B19 foi de 87% dos recĂ©m-nascidos. A prevalĂȘncia de anticorpos IgG de origem materna decaiu exponencialmente atĂ© o 19o mĂȘs de idade. Baixa prevalĂȘncia de anticorpos foi observada nos primeiros quatro anos de vida, aumentando atĂ© 72% no grupo etĂĄrio de 31-40 anos. A idade mĂ©dia de aquisição da primeira infecção nesta comunidade Ă© de 21 ± 7 anos. A idade Ăłtima para se vacinar as crianças desta comunidade com uma vacina hipotĂ©tica Ă© de um ano de idade. CONCLUSÕES: A prevalĂȘncia de anticorpos IgG ao parvovĂ­rus B19 foi alta entre recĂ©m-nascidos e no grupo etĂĄrio 31-40 anos. A anĂĄlise por estrutura etĂĄria mostrou padrĂŁo similar aos estudos prĂ©vios relacionados Ă  baixa prevalĂȘncia de infecção em crianças que aumenta com a idade.OBJECTIVE: To analyze the prevalence of IgG antibodies to human parvovirus B19. METHODS: Cross-sectional study in a suburban community in SĂŁo Paulo, Southeastern Brazil, between November 1990 and January 1991. Randomly selected (N=435) representative samples of sera were collected from healthy children older than 15 days old and adults up to 40 years old. IgG antibodies were detected using ELISA. RESULTS: High prevalence of IgG antibodies to B19 parvovirus was found in 87% of newborns. The prevalence of maternally derived IgG antibodies exponentially plunged up to the 19th month of age. Low prevalence of antibodies was found in the first 4 years of life, increasing up to 72% in those aged 31-40 years. It was estimated that the average age of first infection in this population is 21 ± 7 years old and the optimal age for vaccination with a hypothetical vaccine would be 1 year of age. CONCLUSIONS: Parvovirus B19 IgG antibody prevalence was high in newborns and those aged 31-40 years. The analysis by age groups showed a pattern similar to that found in previous studies, i.e., low prevalence of infection in children that increases with age

    Impact de l'introduction des légumineuses dans les systÚmes de culture sur les émissions de protoxyde d'azote

    Get PDF
    Dans un objectif d'attĂ©nuation du rĂ©chauffement climatique, la mise en place de systĂšmes de culture plus autonomes vis - Ă  - vis des engrais minĂ©raux devient incontournable pour rĂ©duire les Ă©missions de gaz Ă  effet de serre (GES) tout en diminuant le coĂ»t de la fertilisation. L'insertion de lĂ©gumineuses dans ces systĂšmes semble ĂȘtre un levier prometteur pour y parvenir. Les Ă©conomies d'azote permises par diffĂ©rents modes d'introduction de lĂ©gumineuses et leur impact sur les Ă©missions de GES ont Ă©tĂ© estimĂ©s et Ă©valuĂ©s en quantifiant au prĂ©alable les flux d'azote dans les systĂšmes avec ou sans lĂ©gumineuses Ă  partir de donnĂ©es issues de dispositifs expĂ©rimentaux prĂ©existants, disponibles dans la bibliographie ou acquises dans de nouveaux essais. L'introduction de lĂ©gumineuses prĂ©sente rĂ©guliĂšrement un impact positif sur la rĂ©duction de l'emploi des engrais azotĂ©s. Le risque d'augmentation de la lixiviation du nitrate dĂ©pend de leur mode d'introduction et de leur place dans les rotations. Enfin, les Ă©missions mesurĂ©es en cul tures principales de lĂ©gumineuses sont gĂ©nĂ©ralement trĂšs significativement rĂ©duites en comparaison des cultures fertilisĂ©es, cependant la dĂ©gradation des rĂ©sidus des lĂ©gumineuses (en culture ou en couverts) peut gĂ©nĂ©rer des Ă©missions de N 2 O corrĂ©lĂ©es Ă  leur impact sur les flux d'azote, variable selon les conditions pĂ©doclimatiques. Ces rĂ©sultats devraient permettre d'Ă©laborer des recommandations pour mieux prendre en compte les lĂ©gumineuses dans la conception de systĂšmes de culture plus autonomes vis - Ă  - vis des engrais azotĂ©s de synthĂšse et moins Ă©metteurs de N 2 0

    Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries

    Get PDF
    BACKGROUND: In a number of malaria endemic regions, tourists and travellers face a declining risk of travel associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are recommended, via national and international policy, to use chemoprophylaxis which has a well recognized morbidity profile. To evaluate whether current malaria chemo-prophylactic policy for travellers is cost effective when adjusted for endemic transmission risk and duration of exposure. a framework, based on partial cost-benefit analysis was used. METHODS: Using a three component model combining a probability component, a cost component and a malaria risk component, the study estimated health costs avoided through use of chemoprophylaxis and costs of disease prevention (including adverse events and pre-travel advice for visits to five popular high and low malaria endemic regions) and malaria transmission risk using imported malaria cases and numbers of travellers to malarious countries. By calculating the minimal threshold malaria risk below which the economic costs of chemoprophylaxis are greater than the avoided health costs we were able to identify the point at which chemoprophylaxis would be economically rational. RESULTS: The threshold incidence at which malaria chemoprophylaxis policy becomes cost effective for UK travellers is an accumulated risk of 1.13% assuming a given set of cost parameters. The period a travellers need to remain exposed to achieve this accumulated risk varied from 30 to more than 365 days, depending on the regions intensity of malaria transmission. CONCLUSIONS: The cost-benefit analysis identified that chemoprophylaxis use was not a cost-effective policy for travellers to Thailand or the Amazon region of Brazil, but was cost-effective for travel to West Africa and for those staying longer than 45 days in India and Indonesia

    Magnitude and frequency variations of vector-borne infection outbreaks using the Ross–Macdonald model : explaining and predicting outbreaks of dengue fever

    Get PDF
    The classical Ross–Macdonald model is often utilized to model vector-borne infections; however, this model fails on several fronts. First, using measured (or estimated) parameters, which values are accepted from the literature, the model predicts a much greater number of cases than what is usually observed. Second, the model predicts a single large outbreak that is followed by decades of much smaller outbreaks, which is not consistent with what is observed. Usually towns or cities report a number of recurrences for many years, even when environmental changes cannot explain the disappearance of the infection between the peaks. In this paper, we continue to examine the pitfalls in modelling this class of infections, and explain that, if properly used, the Ross–Macdonald model works and can be used to understand the patterns of epidemics and even, to some extent, be used to make predictions.We model several outbreaks of dengue fever and show that the variable pattern of yearly recurrence (or its absence) can be understood and explained by a simple Ross–Macdonald model modified to take into account human movement across a range of neighbourhoods within a city. In addition, we analyse the effect of seasonal variations in the parameters that determine the number, longevity and biting behaviour of mosquitoes. Based on the size of the first outbreak, we show that it is possible to estimate the proportion of the remaining susceptible individuals and to predict the likelihood and magnitude of the eventual subsequent outbreaks. This approach is described based on actual dengue outbreaks with different recurrence patterns from some Brazilian regions

    Seroprevalence of human parvovirus B19 in a suburban population in SĂŁo Paulo, Brazil

    Get PDF
    OBJECTIVE: To analyze the prevalence of IgG antibodies to human parvovirus B19. METHODS: Cross-sectional study in a suburban community in SĂŁo Paulo, Southeastern Brazil, between November 1990 and January 1991. Randomly selected (N=435) representative samples of sera were collected from healthy children older than 15 days old and adults up to 40 years old. IgG antibodies were detected using ELISA. RESULTS: High prevalence of IgG antibodies to B19 parvovirus was found in 87% of newborns. The prevalence of maternally derived IgG antibodies exponentially plunged up to the 19th month of age. Low prevalence of antibodies was found in the first 4 years of life, increasing up to 72% in those aged 31-40 years. It was estimated that the average age of first infection in this population is 21 ± 7 years old and the optimal age for vaccination with a hypothetical vaccine would be 1 year of age. CONCLUSIONS: Parvovirus B19 IgG antibody prevalence was high in newborns and those aged 31-40 years. The analysis by age groups showed a pattern similar to that found in previous studies, i.e., low prevalence of infection in children that increases with age

    Halal dating: changing relationship attitudes and experiences among young British Muslims

    Get PDF
    Young Muslims in the UK are making space to gain greater control over their personal lives through the diction of ‘halal’ and ‘haram’ when reflecting on and negotiating personal relationships. This article explores the significance of ‘halal dating’ within the lived experiences and sexual relationships of young British Muslims. It draws upon 56 in-depth interviews conducted with young (16–30 years) British Muslims of Pakistani heritage. This research shows that, contrary to popular stereotype and widespread expectations, many young British Muslims do date, or have dated. By entertaining the idea that certain forms of dating may be halal, these young Muslims are finding and claiming agency to make relationship choices of their own
    • 

    corecore